DARPP-32 (dopamine and cAMP-regulated phosphoprotein, Mr 32,000) is a membrane protein in the bovine parathyroid  by Matovcik, Lisa M. et al.
FEBS 15431 FEBS Letters 364 (1995) 67 74 
DARPP-32 (dopamine and cAMP-regulated phosphoprotein, Mr 32,000) 
is a membrane protein in the bovine parathyroid 
Lisa M. Matovcik a'b'*, Hugh C. Hemmings Jr. c, Barbara K. Kinder a 
"Department of Surgery, West Haven Department of Veterans Affairs Medical Center, and Yale University School of Medicine, 
New Haven, CT 06510-8062, USA 
bDepartment of Cell Biology, West Haven Department of Veterans Affairs Medical Center, and Yale UniversiO' Sehool of Medicine. 
New Haven, CT 06510-8062, USA 
CLaboratory of Molecular and Cellular Neuroscience, The Rockefeller University, 1230 York Ave., New York, NY 10021, USA 
Received 1 March 1995; revised version received 21 March 1995 
Abstract A distinct form of DARPP-32, a protein phosphatase- 
1 inhibitor, has been identified in bovine calf parathyroid glands. 
Immunoblot analysis of parathyroid tissue revealed a 32 kDa 
protein present predominantly in a particulate fraction; it re- 
mained particulate after treatment with 1.0 M NaCI or 0.1 M 
Na2CO 3. Metabolic labeling of parathyroid cells with mevalon- 
olactone demonstrated that DARPP-32 is isoprenylated, lm- 
munocytocbemical ocalization studies demonstrated that 
DARPP-32 is present in vesicles throughout the cytoplasm of 
parathyroid cells, and that protein phosphatase-13, is concen- 
trated in the region of the plasma membrane. Thus, in contrast 
to the predominately soluble form of DARPP-32 that has been 
characterized in selected areas of the central nervous system, the 
parathyroid form is tightly associated with intracellular mem- 
branes. 
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I. Introduction 
The parathyroid glands maintain the blood calcium concen- 
tration within a very narrow range by sensing small changes in 
free Ca 2÷ via the Ca 2+ receptor [1] and responding with altered 
secretion of parathyroid hormone (PTH) [2]. The parathyroid 
cell is unusual among secretory systems in exhibiting an inverse 
2+ 2+ secretory response to Ca c - Low extracellular calcium (Ca e ) stim- 
ulates PTH secretion, and high Ca2~ * inhibits secretion [3,4]. 
PTH secretion from dispersed bovine parathyroid cells is also 
stimulated by agents that increase intracellular cAMP [5-7]. 
The parathyroid cell has dopamine receptors of the D~ subclass 
that share pharmacological and structural homology with stri- 
atal neuron D~ receptors [8,9]. Dopamine can act independently 
of Ca2~ +to activate adenylyl cyclase and increase cAMP produc- 
tion [10,11]. Ca :+ and cAMP interact o modulate short-term 
changes in PTH release. The intracellular Ca 2÷ (Ca 2+) concentra- 
tion determines the sensitivity to cAMP; a greater increase in 
cAMP is necessary at high Ca 2+ than at low Ca2~ to achieve the 
same level of PTH secretion [12-14]. Thus, signals that act via 
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Ca 2+ may attenuate cAMP-regulated processes in the parathy- 
roid [15]. The proteins that are the targets of regulation by Ca 2+ 
and cAMP are not yet well defined. 
DARPP-32 (dopamine and cAMP-regulated phosphopro- 
tein of 32 kDa) is a regulated phosphoprotein; phosphorylated 
DARPP-32 is an inhibitor of protein phosphatase-1 [ 6], and 
the dephosphorylated form is inactive. DARPP-32 integrates 
the signals of intracellular messengers [15]; in neural tissue 
several signal transduction pathways have been demonstrated 
to converge upon DARPP-32, including those stimulated by 
dopamine, VIP and isoproterenol [17 19]. The firing rate of 
striatal neurons is regulated by inhibitory dopaminergic nput 
from the substantia nigra and excitatory glutamatergic input 
from the neocortex. Dopamine acting through the D~ receptor 
leads to an increase in cAME activation of cAMP-dependent 
protein kinase, and phosphorylation f DARPP-32. Glutamate 
activates the NMDA subclass of glutamate receptors to in- 
crease Ca 2+ influx, which leads to the activation of calcineurin, 
a Ca 2+ and calmodulin-dependent phosphatase, and results in 
the dephosphorylation f DARPP-32. The degree of phospho- 
rylation of DARPP-32, and thus its ability to inhibit protein 
phosphatase-1, is controlled by the antagonistic actions of Ca 2+ 
and cAMP [15]. 
DARPP-32 and its target, protein phosphatase-1, may be 
involved in the interaction of the Ca 2+ and cAMP signaling 
pathways in the parathyroid cell and in regulating PTH secre- 
tion. DARPP-32 has been localized to the bovine parathyroid 
by radioimmunoassay [17] and to human parathyroid chief cells 
by immunofluorescence microscopy [20]. The present study 
examines the subcellular location of parathyroid DARPP-32 
and demonstrates that parathyroid DARPP-32, in contrast o 
brain DARPP-32, is not predominantly a soluble protein, but 
rather is tightly bound to intracellular membranes. 
2. Materials and methods 
Bovine parathyroid glands were collected from newborn calves at a 
local abattoir (DeMartino's, Seymour, CT), or were shipped on wet-ice 
from Florida Biologicals, Highland City, FL. Human parathyroid ade- 
noma tissue was obtained at surgery in accordance with Yale human 
subjects protocols. Ca 2÷, Mg2*-free MEM (Minimal Essential Medium 
(Eagle)) was formulated by Gibco, Grand Island, NY. Ham's F12 
media, fetal calf serum and penicillin/streptomycin were also purchased 
from Gibco. Electrophoresis reagents were purchased from Bio-Rad, 
Richmond, CA. Immobilon was purchased from Millipore, Bedford, 
MA. ~25I-Labeled rabbit anti-mouse secondary antibody and RS-[5- 
SH(N)]mevalonolactone were purchased from New England Nuclear 
(DuPont), Boston, MA. Chemiluminescent reagents were purchased 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)00359-2 
68 L.M. Matovcik et al./FEBS Letters 364 (1995) 67-74 
from Amersham, Arlington Heights, 1L. Collagenase D was purchased 
from Boehringer Mannheim, Indianapolis, IN, and type 3 collagenase 
from Worthington, Freehold, NJ. DNAse I, n-octyl fl-D-glucopyra- 
noside (fl-octylglucoside) and proteinase K were purchased from 
Sigma, St. Louis, MO. Trans-35S-label was purchased from ICN Bi- 
omedicals, Irvine, CA. Percoll was purchased from Pharmacia, 
Uppsala, Sweden. Compactin, purified from the culture broth of Pen# 
cilium citrinum [21], was a generous gift from Dr. A. Endo, Tokyo, 
Japan. 
Rabbit anti-PTH was purchased from Biomeda, Foster City, CA. 
Mouse monoclonal anti-DARPP-32 (5a) and rabbit antiserum to 
DARPP-32 (R2) have been previously characterized [17]. Rabbit poly- 
clonal antibody specific for the gamma isoform of protein phosphatase- 
1 (RU-31) has been characterized ( a Cruz e Silva and Greengard, 
manuscript inpreparation). TRITC (tetramethylrhodamine isothiocya- 
nate)-labeled goat anti-mouse immunoglobulin a d FITC (fluorescein 
isothiocyanate)-labeled goat anti-rabbit F(ab')2 were purchased from 
Tago, Burlingame, CA. 
2.1. Immunofluorescence and electron microscopy 
Dissociated parathyroid cells were incubated overnight on glass 
coverslips in Ham's F12 medium supplemented with 2 mM glutamine, 
10% fetal calf serum, and 10 units/ml penicillin, and 10 ¢tg/ml strepto- 
mycin at 37°C in an atmosphere of 95% air/5% CO2. The cells were 
fixed in 2% formaldehyde made from paraformaldehyde in 75 mM 
sodium phosphate, pH 7.4 for 45 min, permeabilized with 0.05% (w/v) 
saponin, incubated for 2 h with monoclonal nti-DARPP-32, followed 
by TRITC-labeled anti-mouse for 1 h. 
Cryosections (4-6/lm) of calf parathyroid glands were fixed as de- 
scribed in [22] and modified in [23]. The fixed tissue was incubated in 
3% goat serum in PBS for 1 h, permeabilized with 0.1% Triton X-100 
in PBS for 10 min, then incubated for 2 h simultaneously with rabbit 
anti-PTH (1:300) and mouse anti-DARPP-32 (1:1000) followed by 
FITC-labeled anti-rabbit (1:200) and TRITC-labeled anti-mouse 
(1:300). Slides were photographed on a Zeiss Axiophot or a 
Zeiss Axiovert 10 microscope quipped with a Bio-Rad (Richmond, 
CA) MRC-600 confocal attachment. 
Parathyroid fractions were prepared for transmission electron mi- 
croscopy by fixation with 3% glutaraldehyde in 0.1 M cacodylate 
buffer, pH 7.4, for 2 h at 4°C, followed by postfixation for 1 h in 1.0% 
osmium tetroxide in the same buffer, dehydration through a graded 
ethanol series and were embedded in Epon. Thin sections were stained 
with uranyl acetate and lead citrate and analyzed with a Philips 300 
electron microscope. 
2.2. Tissue preparation and Jractionation 
Parathyroids were trimmed free of connective tissue, minced to a fine 
slurry and homogenized by hand with 10 strokes of a ground-glass 
homogenizer at20% (w/v) in homogenization buffer consisting of 0.3 
M sucrose, 10 mM Tris-HCl, pH 7.6, 2.0 mM ethylenediamine tetrace- 
tic acid (EDTA), 1.0 mM dithiothreitol (DTT), and a cocktail of pro- 
tease inhibitors composed of leupeptin, chymostatin, pepstatin, soy- 
bean trypsin inhibitor and aprotinin [24]. The homogenate was centri- 
fuged at 600 x g for 20 min and the pellet discarded, resulting in a 
postnuclear supernatant. Discontinuous sucrose gradients consisted of 
steps of 0.8 M, 1.3 M, 1.7 M sucrose above a 3.0 M cushion in 10 mM 
Tris-HCl, pH 7.6, and 2.0 mM EDTA [25]. Gradients were centrifuged 
at 145,000 z g for 1 h in an SW40 rotor at 4°C. Rat midbrain was 
homogenized aspreviously described [26]. 
2.3. Primary parathyroid cell preparation 
Cells were prepared from calf parathyroids by previously described 
methods [27,28] with the following modifications. Trimmed parathy- 
roid tissue (3.0-3.5 g, i.e. approximately 36 glands) was digested with 
0.036% collagenase D and 0.004% DNAse I in 50 ml of Ca2+/Mg2+-free 
MEM supplemented with 0.5 mM CaCI:, 0.5 mM MgSO4, 3.2 mM 
e-methionine and 10 mM HEPES, pH 7.47. The resulting bovine para- 
thyroid cells were separated from debris, non-viable cells and red cells 
on a 30% (v/v) self-forming Percoll gradient [13]. The optimal disper- 
sion conditions for human parathyroid cells differed slightly from those 
used to obtain bovine cells. Human tissue (1 2 g) was digested with 
0.032% type 3 collagenase and 0.002% DNAse I in 50 ml of Ca2+/Mg 2+- 
free MEM supplemented as described above; the parathyroid cells were 
then isolated on a 30% Percoll gradient. 
2.4. lmmunoprecipitation a d immunoblotting 
Immunoprecipitation of DARPP-32 was performed in RIPA buffer 
[29] using rabbit polyclonal anti-DARPP-32. For immunoblot analysis, 
proteins were separated by SDS-polyacrylamide g l electrophoresis 
(10% acrylamide gels) [30] and transferred to Immobilon [31]. The 
membranes were blocked with 5% non-fat dry-milk in 0.1 M NaC1, 10 
mM Tris-HC1, pH 7.4, 0.1% (v/v) Triton X-100. Primary antibody 
incubations were performed overnight at 4°C with a 1:2000 dilution 
of monoclonal anti-DARPP-32 or a 1 : 1000 dilution of anti-protein 
phosphatase-ly. Antibody detection was performed either by incuba- 
tion for 1 h in a solution of ~25I-labeled goat anti-mouse IgG diluted 
1:1000, or by chemiluminescent detection according to the manu- 
facturer's instructions. Autoradiography was performed with Kodak 
XAR or XRP film. 
2.5. Radioisotopic labeling 
Parathyroid cells were prepared and 1.5 x 106 cells/ml were incu- 
bated overnight in Ham's F12 medium, 10% (v/v) dialyzed (vs. 0.15 M 
NaC1) fetal calf serum, 10 units/ml penicillin, 10 ~tg/ml streptomycin, 
50 ,uCi/ml RS-[5-3H(N)]mevalonolactone and 100 ArM compactin [32]. 
In parallel, 1.0 x 106 cells/ml were incubated in methionine-free MEM, 
10% dialyzed fetal calf serum, penicillin/streptomycin and 300/~Ci/ml 
Trans-35S-label. After labeling, the cells were washed in Ham's F12 
medium and solubilized with RIPA buffer in preparation for im- 
munoprecipitation. 
3. Results 
3.1. Immunofluorescent localization of  parathyroid DARPP-32 
Cells dissociated from bovine parathyroid tissue were 92- 
97% viable as assessed by Trypan blue exclusion. Fig. 1A de- 
picts a cluster of dispersed bovine parathyroid cells labeled with 
monoclonal anti-DARPP-32 and visualized by indirect im- 
munofluorescence. DARPP-32 immunoreactivity was specifi- 
cally localized to small vesicular structures distributed through- 
out the cell cytoplasm, and absent from the nucleus (n). Fig. 1B 
depicts a similar cluster of dispersed human parathyroid cells; 
DARPP-32 immunoreactivity was observed in a vesicular com- 
partment hat is indistinguishable from that observed in bovine 
cells. 
Frozen sections of an intact bovine parathyroid gland were 
double labeled with mouse anti-DARPP-32 (Fig. 1C,E) and 
rabbit anti-PTH (Fig. 1D,F). PTH was present in secretory 
granules of the chief cells. DARPP-32 was observed primarily 
in parathyroid cells, and was also observed rarely in nerve 
terminals in the parathyroid, but was not detected in the endo- 
thelium, adipose tissue or other connective tissue in the gland. 
DARPP-32 immunoreactivity in the parathyroid was preserved 
and the vesicular signal appeared identical after fixation of the 
tissue with acetone, 2% formaldehyde, formaldehyde-lysine- 
periodate [33], or formaldehyde-PIPES-tetraborate [22].
The intracellular distribution of DARPP-32 is predomi- 
nantly vesicular, but is not identical with that of PTH. The 
arrows in Fig. 1E,F point to selected regions in which DARPP-  
32 and PTH appeared to be associated with the same granule. 
The degree of overlap is difficult to quantify at the light level 
even with confocal optics because of the large number of PTH 
and DARPP-32 positive organelles; however, DARPP-32 ap- 
peared to colocalize with only a small fraction of the total PTH 
granule population. 
3.2. Parathyroid DARPP-32 is localized to a particulate 
subcellular fraction 
The presence of immunoreactive DARPP-32 in bovine para- 
thyroid was examined by immunoblot analysis, and its subcel- 
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Fig. 1. (A,B) Indirect immunofluorescence lo alization of DARPP-32 in dissociated bovine (A) and human (B) parathyroid cells. Fixed, permeabilized 
cells were labeled with monoclonal nti-DARPP-32 (1 : 600), the signal was detected with TRITC-labeled anti-mouse antibody, and visualized using 
confocal microscopy. Magnification = 1200x. (C,D,E,F) Double indirect immunofluorescence localization of DARPP-32 and PTH in bovine 
parathyroid. A cryosection of parathyroid tissue was incubated simultaneously with mouse anti-DARPP-32 (C,E) and rabbit anti-PTH (D,F), and 
the signal was detected with a mixture of TRITC-anti-mo~e and FITC anti-rabbit secondary antibodies. The arrows in (E) and (F) denote regions 
of colocalization between DARPP-32 and PTH. Magnification (C and D) = 630x; (E and F) = 1260x. 
lular distribution compared to that of rat midbrain (Fig. 2). In 
the rat brain, as shown previously, DARPP-32 was present 
predominantly in the supernatant ascompared to the pellet; the 
'particulate' DARPP-32 has been shown to be in the cytosol of 
synaptosomes, which sediment under the centrifugation condi- 
tions used [34]. In contrast, in the parathyroid gland most of 
the DARPP-32 was found in the pellet. This difference in 
subcellular location was unexpected, and suggests that parathy- 
roid DARPP-32 may be associated with either cytoskeleton or 
membrane-bound organelles. The apparent molecular mass of 
particulate bovine parathyroid DARPP-32 was the same as that 
of rat brain DARPP-32, but the small amount of DARPP-32 
in the bovine parathyroid soluble fraction had a slightly higher 
molecular mass. On some gels soluble parathyroid DARPP-32 
appeared as a doublet, and on some gels as a triplet; the band 
of lowest molecular mass always co-migrated with particulate 
bovine parathyroid DARPP-32. 
Further subcellular fractionation was performed to localize 
parathyroid DARPP-32 more specifically. DARPP-32 purified 
from bovine caudate nucleus [26] is shown in Fig. 3A, lane 1. 
DARPP-32 present in a P10 fraction prepared by centrifuging 
bovine parathyroid postnuclear supernatant 10,000 x g for 10 
min migrated with a slightly higher molecular mass than the 
bovine brain DARPP-32 (lane 2). This is consistent with the 
observations that: (a) rat brain DARPP-32 migrated with a 
higher molecular mass than bovine brain DARPP-32 [17]; and 
(b) bovine parathyroid particulate DARPP-32 co-migrated 
with rat brain DARPP-32 (Fig. 2). Lane 3 shows three forms 
of parathyroid DARPP-32 present in the soluble S 100 fraction 
prepared by centrifuging the S10 supernatant of the P10 pellet 
at 100,000 x g for 1 h. The predominant band had a molecular 
mass several kilodaltons greater than in the PI0 fraction; two 
minor bands were visible at a lower molecular mass, the smaller 
of which co-migrated with P10 DARPP-32. No DARPP-32 was 
observed in the P100 fraction (the pellet formed after centrifu- 
gation of the S10 for 100,000 x g for 1 h) (lane 4). The P10 
fraction (lane 2), which contained most of the parathyroid 
DARPP-32, was subfractionated on a discontinuous sucrose 
gradient resulting in four fractions hown in order of increasing 
density (lanes 5 8). Lane 6 contained material sedimenting at 
1 
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PARATHYROID BRAIN 
Fig. 2. DARPP-32 is predominantly soluble in brain and particulate in
parathyroid. Rat midbrain postnuclear supernatant and bovine para- 
thyroid postnuclear supernatant were centrifuged at 100,000 x g for 
1 h and the resulting supernatants (S) and pellets (P) were subjected 
to immunoblot analysis with monoclonal anti-DARPP-32 followed 
by horseradish peroxidase labeled sheep anti-mouse immunoglobulin; 
the complex was detected by enhanced chemiluminescence. Parathy- 
roid, 50 mg protein/lane; brain 5 mg protein/lane. 
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Fig. 3. (A) Distribution of DARPP-32 in subcellular f actions of bovine parathyroid. Bovine parathyroid postnuclear supernatant was fractionated, 
and the fractions analyzed by immunoblot analysis with monoclonal anti-DARPP-32 followed by [~25I]rabbit anti-mouse immunoglobulin. Lane 
1 = bovine caudate nucleus DARPP-32 (64 ng protein); lane 2 = P10 (100~tg protein); lane 3 = S100 (200pg protein); lane 4 = P100 (100pg protein); 
lanes 5 8 = 4.4 mg of P10 protein was loaded on the top of a 4-step sucrose density gradient, and centrifuged for 1 h at 145,000 × g in an SW40 rotor 
at 4°C. The protein at the interfaces was collected, and each fraction was examined (100,ug protein). Lane 5 -- <0.8 M sucrose (density < 1.10); lane 
6 = 0.8 1.3 M sucrose (density 1. l~ l .  17); lane 7 = 1.3-1.7 M sucrose (density 1.17-1.21); lane 8 = > 1.7 M sucrose (density > 1.21). (B) Morphological 
characterization f the 0.8-1.3 M sucrose gradient fraction. Magnification = 12,500x. 
the 0.8 M-1.3 M interface, and has the majority of parathyroid 
DARPP-32. 
This gradient fraction represents 64% of the protein in the 
P10 fraction and approximately 15% of the total parathyroid 
protein. The majority of PTH is detected by immunoblot in this 
fraction (not shown), the density of which (1.17 1.21) corre- 
sponds approximately to the density of the heavier two of the 
three major subpopulations of PTH granules isolated on metri- 
zamide sucrose gradients previously described by Bajpai and 
Hamilton [35]. Electron microscopic examination (Fig. 3B) 
confirms that it is enriched in secretory granules (sg), as well 
as mitochondria (m), multivesicular bodies (mvb) and unidenti- 
fied vesicles and cytoskeletal fragments. 
3.3. Parathyroid DARPP-32 has a cytoplasmic exposure 
To determine if DARPP-32 is present within a membrane- 
bound structure, or is exposed to the cytoplasmic surface, lim- 
ited protease digestion was used to selectively degrade proteins 
which are exposed to the cytoplasmic surface. Proteinase K, a 
non-specific protease, was added to the salt-washed PI0 frac- 
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Fig. 4. DARPP-32 has a cytoplasmic exposure in the bovine parathyroid. The P I0 fraction was suspended in250 mM NaC1, resedimented at 10,000 x g 
for 20 min, then treated on ice for 1 h with proteinase K. The proteinase K:protein ratio (w/w) ranges from 0:100 to 1 : 100. lmmunoblot of 
DARPP-32:100/tg protein/lane, 10% polyacrylamide gel. Immunoblot of PTH: 30 ¢tg protein/lane, 15% polyacrylamide gel. 
tion for 1 h on ice [36]. The sample was divided between two 
polyacrylamide gels, then DARPP-32 and PTH were each de- 
tected by immunoblot  (Fig. 4). 
In the absence of proteinase K, or in the presence of low 
concentrat ions of proteinase K (0-1 : 10,000), neither DARPP-  
32 nor PTH was degraded. Intermediate concentrations 
(1:7500-1:250) result in progressively increasing DARPP-32 
degradation, while PTH remains intact. High concentrat ions 
(1:100) of proteinase K presumably disrupted the secre- 
tory granules, and began to degrade PTH. Almost no digestion 
products of DARPP-32 were observed, presumably either be- 
cause the fragment containing the monoclonal  epitope was too 
small to detect by immunoblot  or the antigenic site was lost. 
Thus, at certain protease concentrat ions DARPP-32 was acces- 
sible to digestion while the intragranular PTH remained inac- 
cessible. This suggests that DARPP-32 has a cytoplasmic orien- 
tat ion in or on the membrane,  as opposed to an intravesicular 
distribution. 
3.4. Parathyroid DARPP-32 is a membrane protein 
To determine the nature of the association of parathyroid 
DARPP-32 with the membrane,  the P10 fraction was treated 
with agents known to release membrane-associated p ripheral, 
but not integral membrane proteins. Following treatment, 
equal amounts of the pellet and supernatant proteins were 
examined for DARPP-32 immunoreactivity by immunoblot  
(Fig. 5). 
All of the immunoreact ive DARPP-32 remained in the pellet 
under control condit ions (lanes 1 and 2) and after treatment 
with 1.0 M NaC1 (lanes 3 and 4), or 0.1 M Na2CO3, pH 11 (lanes 
5 and 6). It was partially removed to the soluble fraction by 
1.0% fl-octylglucoside (lanes 7 and 8). It was removed to the 
soluble fraction by 1.0% SDS (lanes 9 and 10). Parathyroid 
DARPP-32 was recovered in the pellet after treatment with 
1.0% Triton X-114 followed by centrifugation at 45,000 x g for 
30 min (data not shown). By these criteria, parathyroid 
DARPP-32 behaved as a membrane protein, and not as a 
classically defined membrane-associated protein. 
3.5. Parathyroid DARPP-32 is" isoprenylated 
To determine if parathyroid DARPP-32 is isoprenylated, 
isolated bovine parathyroid cells were labeled overnight with 
1 2 3 4 5 (, 7 S ~ I 41 
Fig. 5. DARPP-32 is tightly bound to membranes of bovine parathy- 
roid cells. The PI0 pellet was prepared by centrifugation at 10,000 x g 
for 20 min at 4°C, then resuspended in homogenization buffer with 1.0 
mM phenylmethylsulfonylfluoride and the following additions: lanes 1 
and 2 = no addition; lanes 3 and 4 = 1.0 M NaCk lanes 5 and 6 = 0.1 
M Na2CO3, pH 11; lanes 7 and 8 = 1.0% (w/v)fl-octylglucoside; lanes 
9 and 10 = 1.0% (w/v) SDS. Supernatant fractions after centrifugation 
at 180,000 x g for 10 min are compared to the resulting pellets. Eighty 
mg protein/lane were examined by immunoblot with monoclonal anti- 
DARPP-32. Lanes 1, 3, 5, 7 and 9 = supernatant: lanes 2, 4, 6, 8 and 
10 = pellet. 
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Fig. 6. Parathyroid DARPP-32 is isoprenylated. Cells labeled with 
RS-[5-3H(N)]mevalonolactone r Trans-35S-label were subjected to 
immunoprecipitation with polyclonal anti-DARPP-32. The major 
immunoprecipitated bands were 32 and 70 kDa. 
50 ¢tCi/ml RS-[5-3H(N)]mevalonolactone, a precursor of 
mevalonic acid, in the presence of compactin, an inhibitor of 
HMG Co-A reductase. The cells remained 94% viable as as- 
sessed by Trypan blue after the compactin treatment. The la- 
beled cells were subjected to immunoprecipitation with polyclo- 
nal anti-DARPP-32. A predominant protein of 32 kDa, and a 
minor 70 kDa protein were observed (Fig. 6). The 70 kDa band 
was observed consistently in immunoprecipitations a d occa- 
sionally in immunoblots; its identity is not known at this time. 
DARPP-32 immunoprecipitated from [35S]methionine-labeled 
cells co-migrated with that immunoprecipitated from RS- 
[5-3H(N)]mevalonolactone-labeled cells. Thus, parathyroid 
DARPP-32 was isoprenylated. This modification of DARPP- 
32 may be responsible in part for the association of DARPP-32 
with intracellular membranes. 
3.6. Protein phosphatase-ly is' located at the periphery of the 
parathyroid cell 
The parathyroid was examined for the presence of the regu- 
latory target of DARPP-32, protein phosphatase-1, with an 
antibody to the y isoform. Fig. 7A shows that a 37 kDa protein 
corresponding to the molecular mass of the catalytic subunit 
of PP-ly was specifically detected in the parathyroid by im- 
munoblot. In the PI0, P100 and S100 fractions there was a 
predominant immunoreactive protein of approximately 37kDa 
that was relatively more abundant in the soluble fraction. 
To further determine the intracellular localization of PP-ly 
in the parathyroid, cryosections of bovine parathyroid were 
labeled with anti-PP-ly (Fig. 7B). PP-ly immunoreactivity was 
present in the majority of chief cells in the cords of parathyroid 
tissue, and was predominantly located at the periphery of the 
cell, in the vicinity of the plasma membrane. Blood vessels and 
nerves also reacted intensely with anti-PP-ly. The distribution 
and intensity of the signal was similar after fixation with ace- 
tone or paraformaldehyde. In control tissue treated identically 
to that shown in Fig. 7B with the exception that no primary 
antibody was used, there is no detectable background fluores- 
cence (Fig. 7C). The PP-1 y detected by immunofluorescence in 
this tissue most likely corresponds to that in the P10 or P100 
fractions, since much of the soluble enzyme may have been lost 
from the cryosection during processing for immunocytochemis- 
try. 
4. Discussion 
This study used a combined immunocytochemical and 
biochemical approach to characterize bovine parathyroid 
DARPP-32 as an isoprenylated, tightly membrane bound pro- 
tein with a cytoplasmic exposure on an intracellular granule 
compartment that is not identical to the PTH secretory granule 
compartment. Subcellular f actionation localizes DARPP-32 to 
a heterogeneous gradient fraction that contains the majority of 
PTH secretory vesicles. The immunocytochemical d ta show 
that parathyroid DARPP-32 is associated with vesicular struc- 
tures distributed throughout the cytoplasm of the cell; however, 
these vesicles are on average slightly smaller than bovine PTH- 
containing secretory granules, which are 0.3-0.5 ~tm in diameter 
[37]. While there is a small degree of overlap between DARPP- 
32 and the secretory granule compartment, the majority of the 
DARPP-32 positive vesicles do not co-localize with secretory 
granules. Thus, although parathyroid DARPP-32 and PTH 
positive organelles co-sediment to similar densities, DARPP-32 
is not primarily a secretory granule membrane component. 
DARPP-32 may selectively associate only with a small subset 
of PTH-containing secretory granules, such as ones destined 
for secretion or for degradation. Alternatively, DARPP-32 may 
be associated with a secretory product other than PTH, or may 
have a function unrelated to secretion. 
Parathyroid DARPP-32 is isoprenylated, a modification that 
may play a role in localizing the protein to specific intracellular 
membranes and mediate reversible membrane binding and di- 
rected vesicular trafficking. Consensus equences for isoprenyl- 
ation contain cysteine residues and are present at the carboxyl- 
terminus [38]. Neither bovine brain nor rat brain DARPP-32 
possess these sequences, nor do they have hydrophobic se- 
quence domains that span the lipid bilayer [3941]. Thus, there 
may be species and tissue-specific forms that result from alter- 
native gene splicing or differing posttranslational modifications 
that are responsible for the localization of parathyroid 
DARPP-32 to intracellular membranes. 
A small amount of parathyroid DARPP-32 is soluble. The 
molecular mass of this soluble form(s) is slightly greater than 
that of the particulate form, and of brain DARPP-32. A possi- 
ble explanation for this observation is the existence of post 
translational modification(s) uch as lipid addition, proteolytic 
cleavage or phosphorylation. The apparent molecular mass on 
SDS-PAGE of caudate DARPP-32 decreases upon phospho- 
rylation of serine-137 by casein kinase I [42]. Thus, if parathy- 
roid DARPP-32 is similar to caudate DARPP-32 in this re- 
spect, the soluble higher molecular mass band(s) may represent 
dephosphorylated or partially phosphorylated forms. 
DARPP-32 is specifically localized to neurons in dopamino- 
ceptive regions of the brain and peripheral tissues with the 
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Fig. 7. (A) Protein phosphatase-1), is present in the bovine parathyroid. 
Lane 1 : P10; lane 2 = P100; and lane 3 = S100 (100 pg protein each) 
were subjected to immunoblot with anti-PP-l~'. The P10, P100 and 
SI00 fractions were prepared as described for Fig. 3. (B,C) Indirect 
immunofluorescence lo alization of PP-1 y in bovine parathyroid tissue. 
(B) A bovine parathyroid cryosection was incubated with anti-PP-ly, 
then FITC-labeled anti-rabbit antibody. (C) In the absence of anti-PP- 
1 y, the secondary antibody produced no signal. Magnification =500 x. 
Dt subclass of dopamine receptors uch as the parathyroid, 
secretory ciliary epithelium, brown adipose tissue, and the renal 
tubule cells of the thick ascending limb of the Loop of Henle 
[20,34,4344]. The parathyroid cell and non-pigmented ciliary 
epithelium secrete PTH and aqueous humor respectively in 
response to stimulation by dopamine. Dopamine results in ther- 
mogenesis inbrown adipose tissue, and may mediate natriuresis 
by the thick ascending limb. Parathyroid DI receptors act 
through the stimulatory guanine nucleotide regulatory protein 
(Gs) to activate adenylyl cyclase and activate cAMP-dependent 
protein kinase [45]. Bovine parathyroids contain high levels of 
dopamine [46]. Nerves innervating rat parathyroids contain 
tyrosine hydroxylase, the enzyme which catalyses dopamine 
synthesis [47]; and catacholamine-containing nerve fibers have 
been demonstrated to be present in the bovine parathyroid [48]. 
Intravenous infusion of high concentrations of dopamine into 
both cattle [48] and humans [49] results in transient increases 
in serum PTH levels. This suggests that dopamine may play a 
previously unappreciated role in regulating parathyroid func- 
tion. 
The primary known regulatory target of DARPP-32 is pro- 
tein phosphatase-1. The data above demonstrate hat at least 
one isoform, PP-ly, is present in both cytosolic and particulate 
fractions of the parathyroid; this is consistent with observations 
of PP-Iy in varying ratios in the soluble and particulate frac- 
tions in cortex, cerebellum, testis, spleen and adrenal [50]. Type 
1 protein phosphatases have a broad range of physiological 
functions, including the regulation of exocytosis [51]. Parathy- 
roid PP-ly is concentrated at the cell periphery in the vicinity 
of the plasma membrane; this is consistent with a role in the 
modulation of PTH secretion. Identification and characteriza- 
tion of parathyroid-specific forms of the components of signal 
transduction pathways may lead to a better understanding of 
the specialized regulation of parathyroid hormone secretion. 
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